跳转至内容
Merck

457442

Sigma-Aldrich

(E)-5-(2-溴乙烯基)尿嘧啶

97%

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H5BrN2O2
CAS号:
分子量:
217.02
MDL编号:
UNSPSC代码:
12352100
PubChem化学物质编号:

方案

97%

表单

solid

mp

189-194 °C (dec.) (lit.)

官能团

bromo

SMILES字符串

Br\C=C\C1=CNC(=O)NC1=O

InChI

1S/C6H5BrN2O2/c7-2-1-4-3-8-6(11)9-5(4)10/h1-3H,(H2,8,9,10,11)/b2-1+

InChI key

BLXGZIDBSXVMLU-OWOJBTEDSA-N

正在寻找类似产品? 访问 产品对比指南

储存分类代码

13 - Non Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jan Balzarini et al.
Molecular pharmacology, 61(5), 1140-1145 (2002-04-19)
The susceptibility of the bicyclic nucleoside analogs (BCNAs), highly potent and selective inhibitors of varicella-zoster virus (VZV), to the enzymes involved in nucleoside/nucleobase catabolism has been investigated in comparison with the established anti-VZV agent (E)-5-(2-bromovinyl)-2'-deoxyuridine [BVDU; brivudine (Zostex)]. Whereas human
H Okuda et al.
The Journal of pharmacology and experimental therapeutics, 287(2), 791-799 (1998-11-10)
A toxicokinetic study was performed using rats to investigate the possible mechanism of 18 acute deaths in Japanese patients with cancer and herpes zoster by interactions of the new oral antiviral drug, sorivudine (SRV), with one of the oral 5-fluorouracil
H Nakayama et al.
Pharmacogenetics, 7(1), 35-43 (1997-02-01)
Sorivudine, 1-beta-D-arabinofuranosyl-5-(E)-(2-bromovinyl)uracil, is a potent antiviral agent against varicella-zoster virus and herpes simplex virus type 1. However, sorivudine should not be used in combination with anticancer drugs such as 5-fluorouracil (5-FU) because (E)-5-(2-bromovinyl)uracil (BVU), a metabolite of sorivudine, inhibits the
S I Kanamitsu et al.
Drug metabolism and disposition: the biological fate of chemicals, 28(4), 467-474 (2000-03-22)
The fatal drug-drug interaction between sorivudine, an antiviral drug, and 5-fluorouracil (5-FU) has been shown to be caused by a mechanism-based inhibition. In this interaction, sorivudine is converted by gut flora to (E)-5-(2-bromovinyl)uracil (BVU), which is metabolically activated by dihydropyrimidine
J Yan et al.
Clinical pharmacology and therapeutics, 61(5), 563-573 (1997-05-01)
Bromovinyl-uracil (BVU) is the principal metabolite of sorivudine, a potent anti-zoster nucleoside. BVU binds to, and irreversibly inhibits, the enzyme dihydropyrimidine dehydrogenase (DPD). The objective of this study was to assess the time course of recovery of DPD activity after

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门